Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Executive Summary

• Highest dose cohort (20 × 8 mg, n=3) showed a mean 4‑point reduction in SDI scores at 24 weeks—exceeding the 3‑point threshold for clinical remission.
• Across dose cohorts 4–9, clinical remission rates rose to 76 % at week 12 and remained high (67 % at week 52); safety profile remains excellent with no SAEs reported in 31 patients over >220 patient‑months.
• Introduction of a new 6 mg/site cohort (Cohort 8b) using larger 19‑gauge catheters resolved prior catheter clogging and produced markedly better histologic and symptom outcomes versus the earlier Cohort 8.

Key Details

• Symptom Response – Highest Dose (Cohort 9):
• Mean SDI reduction = 4.0 points at week 24 (clinical remission defined as ≥3‑point drop).
• Clinical Remission Across Cohorts 4–9:
• Week 12: 59 % (13/22) achieved remission.
• Week 24: 76 % (13/17) maintained remission.
• Week 52: 67 % (6/9) maintained remission.
• Cohort 8b vs Cohort 8 (6 mg/site):
• EoEHSS Stage reduction: –0.38 vs –0.08.
• EoEHSS Grade reduction: –0.38 vs –0.12.
• SDI reduction: –3.8 vs –0.3.
• Peak eosinophil reduction: 65.2 % vs 30.6 %.
• Safety & Tolerability:

• 220 patient‑months of follow‑up; no SAEs reported.

• No cases of oropharyngeal candidiasis, adrenal insufficiency, or glucose derangement.
• One patient lost to follow‑up at six months (Cohort 8).
• Operational Note:
• Catheter clogging observed at 6 mg/site with 21‑gauge catheters; resolved by switching to 19‑gauge catheters, enabling successful dosing in Cohort 8b and ongoing Phase 2b.
• Phase 2b Update:
• Recruiting both 120 mg (20 × 6 mg) and 160 mg (20 × 8 mg) dose arms.
• Top‑line data expected Q3 2026.

Notable Quotes

“We are very pleased to see such a meaningful symptom response at 24 weeks in the highest dose… This type of response based on a single administration procedure would represent a compellingly different option for EoE patients.” – Dr. James A. Helliwell, CEO

All boilerplate and forward‑looking disclaimer sections have been omitted.